Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
171.5 USD | +1.50% | +0.66% | +10.68% |
06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
06-28 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.68% | 303B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B | |
+0.20% | 120B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie CEO to Retire; COO Robert Michael Named Successor